Furthermore, urine circulating tumor DNA markers (i.e., mutated TP53, methylated RASSF1a, and GSTP1) were able to detect early-stage HCC patients, especially those with low AFP levels [37]. This evidence concerns the gene RASSF1 and hepatocellular carcinoma.